OBJECTIVES: An estimated 55-90% of patients with rheumatoid arthritis have foot problems. Therapeutic footwear is frequently prescribed as part of usual care, but data on its use and effect is incomplete. This study aimed to investigate the use and effects of therapeutic footwear. METHODS: Patients with rheumatoid arthritis receiving custom-made therapeutic footwear for the first time formed an inception cohort. Patients reported their therapeutic footwear use on 3 consecutive days in activity diaries 14 and 20 weeks after delivery of the footwear. The Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) was used as the primary outcome of lower-extremity-related pain and activity limitations, and the Health Assessment Questionnaire (HAQ) as a secondary outcome measure of activity limitations, both at baseline and 26 weeks after therapeutic footwear delivery. RESULTS: The cohort comprised 114 rheumatoid arthritis patients (median disease duration 10 years). Mean (standard deviation) therapeutic footwear use was 54 (25)% of the time patients were out of bed. The median (interquartile range) WOMAC score improved from 41 (27-59) to 31 (16-45) (p < 0.001). Secondary outcome measures improved significantly. CONCLUSION: Therapeutic footwear was used with moderate intensity by most rheumatoid arthritis patients and was associated with a substantial decrease in pain and activity limitations. Therapeutic footwear is a relevant treatment option for patients with rheumatoid arthritis and foot problems.
OBJECTIVES: An estimated 55-90% of patients with rheumatoid arthritis have foot problems. Therapeutic footwear is frequently prescribed as part of usual care, but data on its use and effect is incomplete. This study aimed to investigate the use and effects of therapeutic footwear. METHODS:Patients with rheumatoid arthritis receiving custom-made therapeutic footwear for the first time formed an inception cohort. Patients reported their therapeutic footwear use on 3 consecutive days in activity diaries 14 and 20 weeks after delivery of the footwear. The Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) was used as the primary outcome of lower-extremity-related pain and activity limitations, and the Health Assessment Questionnaire (HAQ) as a secondary outcome measure of activity limitations, both at baseline and 26 weeks after therapeutic footwear delivery. RESULTS: The cohort comprised 114 rheumatoid arthritispatients (median disease duration 10 years). Mean (standard deviation) therapeutic footwear use was 54 (25)% of the time patients were out of bed. The median (interquartile range) WOMAC score improved from 41 (27-59) to 31 (16-45) (p < 0.001). Secondary outcome measures improved significantly. CONCLUSION: Therapeutic footwear was used with moderate intensity by most rheumatoid arthritispatients and was associated with a substantial decrease in pain and activity limitations. Therapeutic footwear is a relevant treatment option for patients with rheumatoid arthritis and foot problems.
Authors: Marloes Tenten-Diepenmaat; Marike van der Leeden; Thea P M Vliet Vlieland; Leo D Roorda; Joost Dekker Journal: Rheumatol Int Date: 2018-03-20 Impact factor: 2.631
Authors: Sytske Anne Bergstra; Iris M Markusse; Gülşah Akdemir; H Karel Ronday; K Huub Han; Willem F Lems; Pit J S M Kerstens; Rosaline van den Berg; Robert B M Landewé; Cornelia F Allaart Journal: Clin Rheumatol Date: 2015-12-22 Impact factor: 2.980
Authors: Patricia Palomo-López; Ricardo Becerro-de-Bengoa-Vallejo; Marta Elena Losa-Iglesias; David Rodríguez-Sanz; César Calvo-Lobo; Daniel López-López Journal: Medicine (Baltimore) Date: 2017-04 Impact factor: 1.889
Authors: Marloes Tenten-Diepenmaat; Marike van der Leeden; Thea P M Vliet Vlieland; Joost Dekker Journal: J Foot Ankle Res Date: 2018-07-04 Impact factor: 2.303
Authors: C J Nester; A Graham; A Martinez-Santos; A E Williams; J McAdam; V Newton; D Sweeney; D Walker Journal: J Foot Ankle Res Date: 2018-03-20 Impact factor: 2.303